<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: should carefully", fill: "#a9203e"},
{source: "2: should carefully", target: "2: following risks", fill: "#a9203e"},
{source: "2: following risks", target: "2: common stock", fill: "#a9203e"},
{source: "2: should carefully", target: "4: Additional ", fill: "#900"},
{source: "4: Additional ", target: "4: presently known", fill: "#900"},
{source: "4: presently known", target: "4: immaterial may also impair", fill: "#900"},
{source: "4: immaterial may also impair", target: "4: operations", fill: "#900"},
{source: "4: Additional ", target: "7: Risks Associated ", fill: "#e3256b"},
{source: "7: Risks Associated ", target: "7: problems principally", fill: "#e3256b"},
{source: "7: problems principally", target: "7: facility", fill: "#e3256b"},
{source: "7: facility", target: "7: accurately", fill: "#e3256b"},
{source: "7: accurately", target: "7: may lose future revenue", fill: "#e3256b"},
{source: "7: may lose future revenue", target: "7: operations may", fill: "#e3256b"},
{source: "7: operations may", target: "7: materially", fill: "#e3256b"},
{source: "7: materially", target: "7: adversely affected", fill: "#e3256b"},
{source: "7: Risks Associated ", target: "17: Additionally ", fill: "#00ff7f"},
{source: "17: Additionally ", target: "17: comply with", fill: "#00ff7f"},
{source: "17: comply with", target: "17: requirements", fill: "#00ff7f"},
{source: "17: requirements", target: "17: connection with", fill: "#00ff7f"},
{source: "17: connection with", target: "17: remediation", fill: "#00ff7f"},
{source: "17: Additionally ", target: "25: issues involve", fill: "#abcdef"},
{source: "25: issues involve", target: "25: management additional cost", fill: "#abcdef"},
{source: "25: management additional cost", target: "25: uncertainty", fill: "#abcdef"},
{source: "25: uncertainty", target: "25: operations", fill: "#abcdef"},
{source: "25: operations", target: "25: net earnings", fill: "#abcdef"},
{source: "25: net earnings", target: "25: deviation from", fill: "#abcdef"},
{source: "25: issues involve", target: "34: future requests", fill: "#a8e4a0"},
{source: "34: future requests", target: "34: may involve", fill: "#a8e4a0"},
{source: "34: may involve", target: "34: additional costs", fill: "#a8e4a0"},
{source: "34: additional costs", target: "34: legal fees", fill: "#a8e4a0"},
{source: "34: legal fees", target: "34: management", fill: "#a8e4a0"},
{source: "34: future requests", target: "36: advised us", fill: "#fffaf0"},
{source: "36: advised us", target: "36: common stock", fill: "#fffaf0"},
{source: "36: common stock", target: "36: options prior", fill: "#fffaf0"},
{source: "36: options prior", target: "36: announcement", fill: "#fffaf0"},
{source: "36: announcement", target: "36: acquisition", fill: "#fffaf0"},
{source: "36: acquisition", target: "36: PharmaNet to the SEC In ", fill: "#fffaf0"},
{source: "36: PharmaNet to the SEC In ", target: "36: December ", fill: "#fffaf0"},
{source: "36: December ", target: "36: staff wrote", fill: "#fffaf0"},
{source: "36: staff wrote", target: "36: requesting various documents principally", fill: "#fffaf0"},
{source: "36: requesting various documents principally", target: "36: compensation", fill: "#fffaf0"},
{source: "36: compensation", target: "36: vice president", fill: "#fffaf0"},
{source: "36: vice president", target: "36: legal affairs", fill: "#fffaf0"},
{source: "36: legal affairs", target: "36: former officers duties", fill: "#fffaf0"},
{source: "36: former officers duties", target: "36: Independent Counsels ", fill: "#fffaf0"},
{source: "36: advised us", target: "83: last six years", fill: "#d70040"},
{source: "83: last six years", target: "83: acquisitions", fill: "#d70040"},
{source: "83: last six years", target: "START_HERE", fill: "#d70040"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Investigate</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Formally complain</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_management">Facility management</a></td>
      <td>Facility management, or facilities management, (FM) is a professional management discipline focused on the efficient and effective delivery of logistics and other support services related to real property, it encompasses multiple disciplines to ensure functionality, comfort, safety and efficiency of the built environment by integrating people, place, process and technology, as defined by the International Organization for Standardization (ISO). The profession is certified through Global Facility Management Association (Global FM) member organizations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_ID">Facility ID</a></td>
      <td>The facility ID number, also called a FIN or facility identifier, is a unique integer number of one to six digits, assigned by the U.S. Federal Communications Commission (FCC) Media Bureau to each broadcast station in the FCC Consolidated Database System (CDBS) and Licensing and Management System (LMS) databases, among others.\nBecause CDBS includes information about foreign stations which are notified to the U.S. under the terms of international frequency coordination agreements, FINs are also assigned to affected foreign stations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_facility">Health facility</a></td>
      <td>A health facility is, in general, any location where healthcare is provided. Health facilities range from small clinics and doctor's offices to urgent care centers and large hospitals with elaborate emergency rooms and trauma centers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Telecommunications_facility">Telecommunications facility</a></td>
      <td>In telecommunications, a facility is defined by Federal Standard 1037C as:\n\nA fixed, mobile, or transportable structure, including (a) all installed electrical and electronic wiring, cabling, and equipment and (b) all supporting structures, such as utility, ground network, and electrical supporting structures.\nA network-provided service to users or the network operating administration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pine_Gap">Pine Gap</a></td>
      <td>Pine Gap is the commonly used name for a satellite surveillance base and Australian Earth station approximately 18 kilometres (11 mi) south-west of the town of Alice Springs, Northern Territory in the centre of Australia. It is jointly operated by Australia and the United States, and since 1988 it has been officially called the Joint Defence Facility Pine Gap (JDFPG); previously, it was known as Joint Defence Space Research Facility.The station is partly run by the US Central Intelligence Agency (CIA), US National Security Agency (NSA), and US National Reconnaissance Office (NRO) and is a key contributor to the NSA's global interception effort, which included the ECHELON program.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Sicilian_Connection">The Sicilian Connection</a></td>
      <td>The Sicilian Connection (Italian: Afyon oppio, French: Action héroïne, also known as The Opium Connection and La filière) is a 1972 Italian-French crime-thriller film directed by Ferdinando Baldi.\n\n\n== Plot ==\nThe Italian-American Joseph Coppola wants to start trafficking drugs from Turkey to the United States and calls for the support of the Sicilian Mafia, who would  protect him from the Marseilles Clan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Cosmic_Connection">The Cosmic Connection</a></td>
      <td>The Cosmic Connection: An Extraterrestrial Perspective is a book by the astronomer Carl Sagan, produced by Jerome Agel. It was originally published in 1973; an expanded edition with contributions from Freeman Dyson, David Morrison, and Ann Druyan was published in 2000 under the title Carl Sagan's Cosmic Connection.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hermitian_connection">Hermitian connection</a></td>
      <td>In mathematics, a Hermitian connection \n  \n    \n      \n        ∇\n      \n    \n    {\displaystyle \nabla }\n   is a connection on a Hermitian vector bundle \n  \n    \n      \n        E\n      \n    \n    {\displaystyle E}\n   over a smooth manifold \n  \n    \n      \n        M\n      \n    \n    {\displaystyle M}\n   which is compatible with the Hermitian metric\n\n  \n    \n      \n        ⟨\n        ⋅\n        ,\n        ⋅\n        ⟩\n      \n    \n    {\displaystyle \langle \cdot ,\cdot \rangle }\n   on \n  \n    \n      \n        E\n      \n    \n    {\displaystyle E}\n  , meaning that\n\n  \n    \n      \n        v\n        ⟨\n        s\n        ,\n        t\n        ⟩\n        =\n        ⟨\n        \n          ∇\n          \n            v\n          \n        \n        s\n        ,\n        t\n        ⟩\n        +\n        ⟨\n        s\n        ,\n        \n          ∇\n          \n            v\n          \n        \n        t\n        ⟩\n      \n    \n    {\displaystyle v\langle s,t\rangle =\langle \nabla _{v}s,t\rangle +\langle s,\nabla _{v}t\rangle }\n  for all smooth vector fields \n  \n    \n      \n        v\n      \n    \n    {\displaystyle v}\n   and all smooth sections \n  \n    \n      \n        s\n        ,\n        t\n      \n    \n    {\displaystyle s,t}\n   of \n  \n    \n      \n        E\n      \n    \n    {\displaystyle E}\n  .\nIf \n  \n    \n      \n        X\n      \n    \n    {\displaystyle X}\n   is a complex manifold, and the Hermitian vector bundle \n  \n    \n      \n        E\n      \n    \n    {\displaystyle E}\n   on \n  \n    \n      \n        X\n      \n    \n    {\displaystyle X}\n   is equipped with a holomorphic structure, then there is a unique Hermitian connection whose (0, 1)-part coincides with the Dolbeault operator \n  \n    \n      \n        \n          \n            \n              \n                ∂\n                ¯\n              \n            \n          \n          \n            E\n          \n        \n      \n    \n    {\displaystyle {\bar {\partial }}_{E}}\n   on \n  \n    \n      \n        E\n      \n    \n    {\displaystyle E}\n   associated to the holomorphic structure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mothership_Connection">Mothership Connection</a></td>
      <td>Mothership Connection is the fourth album by American funk band Parliament, released on December 15, 1975 on Casablanca Records. This concept album is often rated among the best Parliament-Funkadelic releases, and was the first to feature horn players Maceo Parker and Fred Wesley, who had previously backed James Brown in the J.B.'s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Project_management">Project management</a></td>
      <td>Project management is the process of leading the work of a team to achieve all project goals within the given constraints. This information is usually described in project documentation, created at the beginning of the development process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agile_management">Agile management</a></td>
      <td>Agile management is the application of the principles of Agile software development to various management processes, particularly project management. Following the appearance of the Manifesto for Agile Software Development in 2001, Agile techniques started to spread into other areas of activity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Network_management">Network management</a></td>
      <td>Network management is the process of administering and managing computer networks. Services provided by this discipline include fault analysis, performance management, provisioning of networks and maintaining quality of service.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Women_Management">Women Management</a></td>
      <td>Women Management is a modeling agency based in New York. Founded by Paul Rowland in 1988,  Women also has two sister agencies, Supreme Management and Women 360 Management, which is also part of the Women International Agency Chain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_management">Emergency management</a></td>
      <td>Emergency management, also called emergency response or disaster management, is the organization and management of the resources and responsibilities for dealing with all humanitarian aspects of emergencies (prevention, preparedness, response, mitigation, and recovery). The aim is to prevent and reduce the harmful effects of all hazards, including disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_mergers_and_acquisitions_by_Alphabet">List of mergers and acquisitions by Alphabet</a></td>
      <td>Google is a computer software and a web search engine company that acquired, on average, more than one company per week in 2010 and 2011. The table below is an incomplete list of acquisitions, with each acquisition listed being for the respective company in its entirety, unless otherwise specified.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ben_Ashkenazy">Ben Ashkenazy</a></td>
      <td>Ben Ashkenazy (born 1968/69) is an American billionaire real estate developer. He is the founder, CEO, and majority owner of Ashkenazy Acquisition Corporation, which has a $12 billion property portfolio.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_acquisitions_by_Oracle">List of acquisitions by Oracle</a></td>
      <td>This is a listing of Oracle Corporation's corporate acquisitions, including acquisitions of both companies and individual products.\nOracle's version does not include value of the acquisition.See also Category:Sun Microsystems acquisitions (Sun was acquired by Oracle).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Library_acquisitions">Library acquisitions</a></td>
      <td>Library acquisitions is the department of a library responsible for the selection and purchase of materials or resources. The department may select vendors, negotiate consortium pricing, arrange for standing orders, and select individual titles or resources.Libraries, both physical and digital, usually have four common broad goals that help dictate these responsibilities.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SFBC INTERNATIONAL INC      Item 1A  <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider the <font color="blue">following risks</font> and all of the other     information set forth in this Form 10-K before deciding to invest in shares     of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">risks described</font> below are not the <font color="blue">only ones facing</font>     us</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not <font color="blue">presently known</font> to us or that we currently deem     <font color="blue">immaterial may also impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks</font> actually occurs, our business, financial     condition or results of <font color="blue">operations</font> would likely suffer</td>
    </tr>
    <tr>
      <td>In such case, the     <font color="blue">market price</font> of our <font color="blue">common stock</font> would likely decline due to the occurrence     of any of these risks, and you may lose all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Associated </font>with Recent Actions, Inquiries and Lawsuits       If we are unable to convince our clients that the <font color="blue">problems principally</font>     related to our Miami <font color="blue">facility</font> were either not <font color="blue">accurately</font> reported or have     been  rectified,  we <font color="blue">may lose <font color="blue">future revenue</font></font> and our future results of     <font color="blue">operations</font> may be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Although the report of the Independent Counsel which our <font color="blue"><font color="blue">Board of Directors</font>     </font>retained  to review the <font color="blue">allegations</font> contained in the <font color="blue">Bloomberg Reports     </font>largely  concluded  that  the Reports’ <font color="blue">allegations</font> were unfounded, the     <font color="blue">repetition</font> of these <font color="blue">allegations</font> in the media has harmed our reputation and     cost us business in our Miami <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>These problems have <font color="blue">been compounded</font>     by the structural and other <font color="blue">local <font color="blue">regulatory</font> <font color="blue">issues <font color="blue">affecting</font></font></font> the real     estate and related <font color="blue">improvements</font> of <font color="blue">the Miami </font><font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Clients may decline     to <font color="blue">give us contracts</font> for studies to be performed by our Miami <font color="blue">facility</font>     unless we can <font color="blue">convince them</font> that the operational <font color="blue">allegations</font> and structural     and other <font color="blue">allegations</font> <font color="blue">affecting</font> the <font color="blue">physical property</font> are not impacting our     ability to <font color="blue">provide first rate <font color="blue">clinical research</font></font> in <font color="blue">compliance with</font> our     client’s protocols and all <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>upon the     amount of <font color="blue">revenue lost</font>, the results may have a material and <font color="blue">adverse affect</font>     on our future results of <font color="blue">operations</font>, including a reduction not only in our     <font color="blue"><font color="blue">net earnings</font> but</font> a <font color="blue">deviation from</font> our <font color="blue">forecasted <font color="blue">net earnings</font></font></td>
    </tr>
    <tr>
      <td>Moreover,     while the loss of business seems to have <font color="blue">been largely confined</font> to our <font color="blue">Miami     </font>operation, we <font color="blue">cannot predict</font> if <font color="blue">clients may withhold</font> business elsewhere</td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [83]Table of <font color="blue">Contents       </font>If we are unable to <font color="blue">deal with</font> all of the <font color="blue">issues <font color="blue">affecting</font></font> the <font color="blue">property upon</font>     which our Miami <font color="blue">facility</font> operates, we <font color="blue">may lose <font color="blue">future revenue</font></font> and our future     results of <font color="blue">operations</font> may be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We  are <font color="blue">presently facing</font> a number of <font color="blue">serious issues with</font> regard to our     <font color="blue">property located</font> in Miami including:         •  Our principal Miami <font color="blue">facility</font> is required to obtain a <font color="blue">building permit by</font>     late April 2006 and to make structural repairs within 180 days thereafter     that are <font color="blue">necessary</font> to operate the <font color="blue">facility</font> in <font color="blue">compliance with</font> applicable     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>•  We very <font color="blue">recently learned</font> that the <font color="blue">County Building Department </font>believes     <font color="blue">the Miami </font><font color="blue">facility</font> should be <font color="blue">classified as</font> a generic I-2 or <font color="blue">institutional</font>     classification</td>
    </tr>
    <tr>
      <td>This <font color="blue">will increase</font> our <font color="blue"><font color="blue">remediation</font> costs unless</font> we appeal     the ruling and are successful</td>
    </tr>
    <tr>
      <td>Additionally, we need to <font color="blue">comply with</font> all Fire     Department <font color="blue">requirements</font> in <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue">remediation</font> plan</td>
    </tr>
    <tr>
      <td>We are     <font color="blue">uncertain whether</font> the <font color="blue">Fire Department </font><font color="blue">will approve</font> our <font color="blue">remediation</font> plan,     <font color="blue">whether <font color="blue">additional</font> revisions will</font> be required and what, if any, costs we     will incur</td>
    </tr>
    <tr>
      <td>•  The owner of the <font color="blue">land lease covering</font> the South building and a small     part of the <font color="blue">central annex</font> has instituted a lawsuit to have the Court declare     that we <font color="blue">defaulted under</font> the land lease, which if <font color="blue">adversely</font> determined, would     cause us to move from the South building and a portion of an annex to the     North <font color="blue">building which would involve</font> a material <font color="blue">cash capital expenditure</font> and     reduce the <font color="blue">bed capacity</font> to <font color="blue">approximately</font> 250 beds</td>
    </tr>
    <tr>
      <td>•  Regardless, if we <font color="blue"><font color="blue">successfully</font> resolve</font> the above problems, we may not     have <font color="blue">sufficient parking</font> to operate either the current <font color="blue">facility</font> or simply the     North building and the majority of the annex</td>
    </tr>
    <tr>
      <td><font color="blue">Construction </font>of a parking     structure not only requires <font color="blue">zoning approval which</font> is a lengthy process, but     <font color="blue">also involves</font> a material cost</td>
    </tr>
    <tr>
      <td>•  While we own an <font color="blue">empty building</font> in the <font color="blue">City of Miami </font>which was operated     by <font color="blue">Clinical Pharmacology Associates </font>before our purchase of it in 2003, we     estimate that it would take six months to obtain the <font color="blue">necessary</font> <font color="blue">regulatory</font>     approvals and make structural <font color="blue">improvements</font> to operate that <font color="blue">property as</font> a     Phase I <font color="blue">clinical trial</font>s <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Presently, we have no intent to re-open     that property</td>
    </tr>
    <tr>
      <td>•  The <font color="blue">issues <font color="blue">affecting</font></font> our Miami <font color="blue">facility</font> and <font color="blue">adverse publicity may also</font>     cause employees to leave us and subjects who <font color="blue">participate</font> in our <font color="blue">Phase I     </font>trials in Miami may decline to do so in the future</td>
    </tr>
    <tr>
      <td>Our attempts to resolve these <font color="blue">issues involve</font> a material amount of attention     from our <font color="blue">management</font>, <font color="blue">additional</font> cost and <font color="blue">uncertainty</font> and may have a material     and  adverse  affect  on our future results of <font color="blue">operations</font>, including a     reduction not only in our <font color="blue"><font color="blue">net earnings</font> but</font> a <font color="blue">deviation from</font> our forecasted     <font color="blue">net earnings</font></td>
    </tr>
    <tr>
      <td>Moreover, we have <font color="blue">been approached by</font> a number of <font color="blue">parties about purchasing</font>     <font color="blue">the Miami </font>property we own</td>
    </tr>
    <tr>
      <td>Our ability to sell this property for its actual     <font color="blue">value will</font> be <font color="blue">impacted by</font> the <font color="blue">uncertainty</font> created by the land lease and the     <font color="blue">pending <font color="blue">litigation</font> as well as</font> the <font color="blue">perception</font> that any sale may be required     by our <font color="blue">future failure</font> to <font color="blue">comply with</font> local <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>In the     event we were required to close <font color="blue">the Miami </font><font color="blue">facility</font>, we may not have the time     or resources to complete the <font color="blue">construction</font> of a new building before losing     all of <font color="blue">the Miami </font>business to <font color="blue"><font color="blue">competitor</font>s</font> or attrition</td>
    </tr>
    <tr>
      <td>While we are <font color="blue">cooperating with</font> the requests of the <font color="blue">Senate Finance <font color="blue">Committee </font>    </font>for <font color="blue">documents</font> and will produce current employees if their presence before     <font color="blue">the <font color="blue">Committee </font></font>or its staff is requested, we are concerned that continued     public <font color="blue">disclosure</font> could cause clients to withhold future work from us</td>
    </tr>
    <tr>
      <td><font color="blue">The United States Senate Finance <font color="blue">Committee </font></font>has twice requested <font color="blue">documents</font>     and/or information from us and we have <font color="blue">complied fully with</font> its requests</td>
    </tr>
    <tr>
      <td>Additionally, two of our <font color="blue">former employees</font> including our <font color="blue">former president</font> and     chairman  have  <font color="blue">voluntarily met with</font> the Committee’s staff</td>
    </tr>
    <tr>
      <td>The public     <font color="blue">disclosure</font> of the Committee’s requests has <font color="blue"><font color="blue">negatively</font> affected</font> our common     stock price</td>
    </tr>
    <tr>
      <td>Future <font color="blue">activities</font> by <font color="blue">the <font color="blue">Committee </font></font>and the public <font color="blue">disclosure</font> of     such  <font color="blue">activities</font> can <font color="blue">again affect</font> our <font color="blue">common stock</font> price and may cause     clients to not                                         23       _________________________________________________________________    [84]Table of <font color="blue">Contents       </font><font color="blue">award us contracts</font> or <font color="blue"><font color="blue">cancel existing</font> contracts</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">future requests</font>     <font color="blue">may involve</font> substantial <font color="blue"><font color="blue">additional</font> costs</font> including <font color="blue">legal fees</font> and diversion     of <font color="blue">management</font> time</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>upon the outcome, the <font color="blue">inquiry by</font> the SEC can result in our being     sued by the SEC and being subject to equitable relief including payment of a     fine and <font color="blue">civil monetary penalties</font></td>
    </tr>
    <tr>
      <td>In July 2005, the NASD <font color="blue">advised us</font> that it had referred the review of trading     in our <font color="blue">common stock</font> and <font color="blue">options prior</font> to the <font color="blue">announcement</font> of our <font color="blue">acquisition</font>     of <font color="blue"><font color="blue">PharmaNet </font>to the SEC In </font>late <font color="blue">December </font>2005, the SEC <font color="blue">staff wrote</font> to us     requesting various <font color="blue">documents</font> principally relating to <font color="blue">compensation</font> payable to     our <font color="blue">former president</font> and chairman, to <font color="blue">compensation</font> payable to our former     <font color="blue">vice president</font> of <font color="blue">legal affairs</font> relating to his <font color="blue">compensation</font> and that of his     family, to other information relating to the former officer’s duties and to     the Independent Counsel’s report</td>
    </tr>
    <tr>
      <td>In addition, on March 28, 2006, the SEC     <font color="blue">staff wrote</font> to us requesting various <font color="blue">documents</font> principally relating to     related <font color="blue">party <font color="blue"><font color="blue">transaction</font>s</font></font>, <font color="blue">compensation</font> of, and other <font color="blue"><font color="blue">arrangements</font> with</font>,     <font color="blue">family members</font> of certain of our employees, internal control and other     <font color="blue"><font color="blue">accounting</font> policies</font>, our <font color="blue">initial public offering</font>, our Form 8-K filed on     June 8, 2005, transcripts of all analyst and <font color="blue">investor <font color="blue">conference calls</font></font> and     all minutes of all <font color="blue">board meetings</font>, including committee meetings, since     January 1, 2000</td>
    </tr>
    <tr>
      <td>Presently, the SEC’s review is an informal inquiry which is     <font color="blue">less serious than</font> a <font color="blue">formal investigation</font> in which the SEC <font color="blue">authorizes</font> its     staff to <font color="blue">issue subpoenas</font> and <font color="blue">investigate certain activity</font></td>
    </tr>
    <tr>
      <td>In addition to     the <font color="blue">documents</font> above, we do know that an investor whose name was submitted to     us by the NASD received a <font color="blue">telephone call</font> in January 2006 from the SEC staff     <font color="blue">inquiring about</font> his purchases of SFBC securities and whether he had advance     knowledge of the <font color="blue">PharmaNet </font><font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>That investor has never been our     employee or our <font color="blue">contractor</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">uncertain whether</font> the SEC <font color="blue">staff will seek</font>     to elevate its <font color="blue">informal inquiries</font> to a <font color="blue">formal investigation</font> or if it does,     whether the SEC will bring an <font color="blue">action against us</font></td>
    </tr>
    <tr>
      <td>Among its remedies are the     filing of a lawsuit seeking injunctive relief requiring us to <font color="blue">comply with</font>     the law and the imposition of fines and <font color="blue">civil monetary penalties</font></td>
    </tr>
    <tr>
      <td>A lesser     remedy  would be to issue a report of <font color="blue">investigation outlining activity</font>     considered  to  violate the law</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>upon the outcome of the SEC     inquiry,  we  <font color="blue">may sustain <font color="blue">significant</font> legal expenses</font> and the costs and     negative  publicity related to a formal SEC <font color="blue">investigation could</font> have a     material adverse effect on our future results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The pending FDA open item and other FDA <font color="blue">inspections may</font> cause clients not to     <font color="blue">award future contracts</font> to us or <font color="blue"><font color="blue">cancel existing</font> contracts</font>, which may have a     material and <font color="blue">adverse affect</font> on our future results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We presently are subject to one matter where the FDA inspectional staff     concluded  that we have <font color="blue">adequately addressed</font> its Form 483 observations     following its inspection of a study and <font color="blue">no further action</font> was required,     whereas the <font color="blue">Division of Scientific Investigations </font>recommended that the data     <font color="blue">generated from</font> this study at our Miami <font color="blue">facility</font> be <font color="blue">disallowed</font> in <font color="blue">connection</font>     with  an <font color="blue">abbreviated new drug application</font></td>
    </tr>
    <tr>
      <td>Additionally, we can expect     <font color="blue">continuing inspections</font> of our <font color="blue">facilities</font> in <font color="blue"><font color="blue">connection</font> with</font> studies we have     conducted in support of <font color="blue">marketing <font color="blue">applications</font></font> or <font color="blue">routine inspections</font> of our     offices/<font color="blue">facilities</font> that have yet to be inspected by the <font color="blue">FDA The FDA </font>has     <font color="blue"><font color="blue">significant</font> authority over</font> the conduct of <font color="blue">clinical trial</font>s, and it has the     power to take <font color="blue">regulatory</font> and <font color="blue">legal action</font> in response to violations of     <font color="blue">clinical standards</font> and subject protection in the form of clinical holds on     studies, civil and criminal fines, injunctions, and other measures</td>
    </tr>
    <tr>
      <td>If the     FDA <font color="blue">issues clinical</font> holds, or obtains injunctions, such actions could result     in <font color="blue"><font color="blue">significant</font> obstacles</font> to future <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Additionally, there is a risk     that these FDA actions, if they result in <font color="blue">significant</font> Form 483 observations,     could cause clients to not <font color="blue">award us future contracts</font> or <font color="blue">cancel existing</font>     contracts</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>upon the amount of <font color="blue">revenue lost</font>, the results may have a     material and <font color="blue">adverse affect</font> on our future results of <font color="blue">operations</font>, including a     reduction not only in our <font color="blue"><font color="blue">net earnings</font> but</font> a <font color="blue">deviation from</font> our forecasted     <font color="blue">net earnings</font></td>
    </tr>
    <tr>
      <td>While  we have <font color="blue">insurance coverage</font> in <font color="blue"><font color="blue">connection</font> with</font> the pending class     actions, the <font color="blue">potential <font color="blue">adverse outcome</font> may exceed</font> our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>We are subject to a number of class actions in <font color="blue">federal court which</font> we expect     will be <font color="blue"><font color="blue">consolidated</font> into one case</font> before a single judge</td>
    </tr>
    <tr>
      <td>Subject to a     dlra250cmam000 deductible, we expect our <font color="blue">insurance carrier will pay</font> all legal and     other costs, any <font color="blue">settlement amount</font> and any <font color="blue">adverse judgment</font>, subject to the     limits of the policies</td>
    </tr>
    <tr>
      <td>If the amount of defense costs and any <font color="blue">agreed upon</font>     settlement or <font color="blue">adverse judgment</font> exceeds the <font color="blue">insurance limits</font>                                         24       _________________________________________________________________    [85]Table of <font color="blue">Contents       </font>or if coverage were otherwise unavailable, our <font color="blue">future earnings</font> and financial     condition  could  be  <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Additionally,     <font color="blue">litigation</font> is <font color="blue">generally</font> time-consuming, and can divert the attention of our     <font color="blue">management</font> and other personnel</td>
    </tr>
    <tr>
      <td>If there is an <font color="blue">adverse outcome</font> in the securities class <font color="blue">action lawsuits</font> that     have been <font color="blue">filed against us</font>, our business may be <font color="blue">materially</font> harmed</td>
    </tr>
    <tr>
      <td>Further,     <font color="blue">defending against</font> these and other <font color="blue">lawsuits may</font> be expensive and <font color="blue">could divert</font>     the attention of our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>A large number of securities class actions and <font color="blue">derivative actions</font> have been     <font color="blue">filed against us</font></td>
    </tr>
    <tr>
      <td>The securities class actions allege that we and certain of     our former and <font color="blue">current officers</font> engaged in violations of the anti-fraud     provisions of the <font color="blue">federal securities laws</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">derivative suits</font> are brought     on behalf of SFBC <font color="blue">against certain</font> of its former and <font color="blue">current officers</font> and/or     <font color="blue">directors</font> alleging, among other things, breaches of <font color="blue">fiduciary duty</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">complaints</font> in these actions seek, among other things, unspecified damages     and <font color="blue">costs <font color="blue">associated with</font></font> the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>As with any <font color="blue">litigation</font> proceeding, we <font color="blue">cannot predict</font> with certainty the     <font color="blue">eventual outcome</font> of these <font color="blue">pending lawsuits</font></td>
    </tr>
    <tr>
      <td>Furthermore, we will have to     <font color="blue">incur expenses</font> in <font color="blue"><font color="blue">connection</font> with</font> these lawsuits, which may be substantial</td>
    </tr>
    <tr>
      <td>In the event of an <font color="blue">adverse outcome</font>, our business could be <font color="blue">materially</font> harmed</td>
    </tr>
    <tr>
      <td>Moreover, responding to and defending the pending <font color="blue">litigation</font> could result in     a <font color="blue">significant</font> diversion of <font color="blue">management</font>’s attention and resources and an     increase in <font color="blue">professional fees</font></td>
    </tr>
    <tr>
      <td>If we are unable to stabilize our <font color="blue">operations</font> in Miami, we may be unable to     <font color="blue">compete <font color="blue">effective</font>ly</font> in that area</td>
    </tr>
    <tr>
      <td>We understand that a <font color="blue">competitor</font> has opened a 125 bed <font color="blue">facility</font> in the Miami,     Florida  area</td>
    </tr>
    <tr>
      <td>This <font color="blue">represents</font> the first <font color="blue">significant</font> local early stage     <font color="blue">competition since</font> we purchased <font color="blue">Clinical Pharmacology Associates </font>two and     one-half years ago</td>
    </tr>
    <tr>
      <td>If clients are <font color="blue">concerned about</font> the <font color="blue">issues referred</font> to in     many  of  the  above <font color="blue">risk factors</font> or if our employees and subjects are     attracted to this new <font color="blue">competitor</font>, we may not be able to <font color="blue">compete <font color="blue">effective</font>ly</font>,     in which case our future <font color="blue">net earnings</font> may be reduced and our <font color="blue">common stock</font>     <font color="blue">price will fall</font></td>
    </tr>
    <tr>
      <td>Additionally, this new competition may <font color="blue">adversely</font> affect our     ability to <font color="blue">recruit subjects</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">risks set forth immediately</font> above as well as those in the balance of     these <font color="blue">risk factors</font> may cause us not to meet our 2006 or <font color="blue">future earnings</font>     guidance, <font color="blue">which could</font> cause our stock price to <font color="blue">fall <font color="blue">substantially</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">regularly provide earnings guidance</font> in <font color="blue">press releases</font> and in public     <font color="blue">conference calls</font></td>
    </tr>
    <tr>
      <td>This guidance is not <font color="blue"><font color="blue">incorporated</font> by reference into</font> this     Report</td>
    </tr>
    <tr>
      <td>The guidance is made in a good <font color="blue">faith belief</font> that we will achieve the     range of net revenue and <font color="blue">earnings per</font> share we forecast</td>
    </tr>
    <tr>
      <td>We very recently     revised our <font color="blue">guidance which</font> was <font color="blue">based upon</font>, among other things, a review of     the business at <font color="blue">the Miami </font>and other <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>That guidance was <font color="blue">based upon</font>     a <font color="blue">consideration</font> of the <font color="blue">relevant risks</font> and a full review of our business     <font color="blue">units as well as</font> our anticipated <font color="blue">outside legal</font> and other <font color="blue">expenses as</font> of the     date of the review</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font><font color="blue">upon future events</font> including the status of our     Miami <font color="blue">facility</font> and <font color="blue">property as</font> well as clients’ <font color="blue">perception</font>s about doing     business with us, we may not achieve the forecasted results</td>
    </tr>
    <tr>
      <td>If we fail to     do so, our revisions of our guidance or our <font color="blue">announcement</font> of our <font color="blue">earnings may</font>     cause our <font color="blue">common stock</font> price to fall, which decline may be material</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">forecasts reflect numerous assumptions concerning</font> our expected performance,     as well as other factors, which are beyond our control, and <font color="blue">which might</font> not     turn out to be correct</td>
    </tr>
    <tr>
      <td>Although we believe that the <font color="blue">assumptions underlying</font>     our  <font color="blue">projections</font>  are  reasonable,  actual results could be <font color="blue">materially</font>     <font color="blue">different</font></td>
    </tr>
    <tr>
      <td>Our  financial  results  are subject to <font color="blue">numerous risks</font> and     <font color="blue">uncertainties</font>, including those identified <font color="blue">throughout</font> these <font color="blue">risk factors</font> and     elsewhere in this Report</td>
    </tr>
    <tr>
      <td>Risks Related to Our Business       We have <font color="blue">grown rapidly over</font> the <font color="blue">last few years</font>, and our growth has placed,     and is expected to continue to place, <font color="blue">significant</font> demands on us</td>
    </tr>
    <tr>
      <td>We  have  grown  rapidly  over  the  <font color="blue">last six years</font>, including through     <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Businesses </font>that <font color="blue">grow rapidly often</font> have <font color="blue"><font color="blue">difficult</font>y managing</font>     their growth</td>
    </tr>
    <tr>
      <td>Our <font color="blue">rapid growth</font> has placed and is expected to continue                                         25       _________________________________________________________________    [86]Table of <font color="blue">Contents       </font>to  place  <font color="blue">significant</font>  demands  on our <font color="blue">management</font>, on our <font color="blue">accounting</font>,     financial, information and other systems and on our business</td>
    </tr>
    <tr>
      <td>Although we     have expanded our <font color="blue">management</font>, we need to <font color="blue">continue recruiting</font> and employing     experienced <font color="blue">executives</font> and <font color="blue">key employees capable</font> of providing the <font color="blue">necessary</font>     support</td>
    </tr>
    <tr>
      <td>In addition, we will need to continue to improve our financial,     <font color="blue">accounting</font>, information and other systems in order to <font color="blue"><font color="blue">effective</font>ly manage</font> our     growth</td>
    </tr>
    <tr>
      <td>In particular, our late stage <font color="blue">clinical trial</font> <font color="blue">management</font> business     <font color="blue">faces stiff competition</font> for <font color="blue"><font color="blue">clinical trial</font> monitors</font> and other experienced     personnel</td>
    </tr>
    <tr>
      <td>Historically,  when  making <font color="blue">acquisition</font>s, we have targeted     <font color="blue">operations</font> that we believe can be operated <font color="blue">as autonomous</font> business units</td>
    </tr>
    <tr>
      <td>As     the  result  of  the  2005  problems in Miami and our change in senior     <font color="blue">management</font>, we have reorganized and are now managing our <font color="blue">operations</font> on a     more <font color="blue">centralized</font> basis from our Princeton, New Jersey <font color="blue">headquarters</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">prior decentralization</font> of our <font color="blue">operations</font> and <font color="blue">systems may</font> create <font color="blue"><font color="blue">difficult</font>ies</font>     for us in the future</td>
    </tr>
    <tr>
      <td>All of our <font color="blue">North American </font><font color="blue">subsidiaries</font>, with the     exception of <font color="blue">PharmaNet </font>and Anapharm, have a common <font color="blue">accounting</font> software     platform</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our <font color="blue">management</font> will be able to manage     our growth and integrate acquired <font color="blue">businesses <font color="blue">effective</font>ly</font> or <font color="blue">successfully</font>, or     that our financial, <font color="blue">accounting</font>, information or other <font color="blue">systems will</font> be able to     <font color="blue">successfully</font> accommodate our external and <font color="blue">internal growth</font></td>
    </tr>
    <tr>
      <td>Our failure to     meet these challenges could <font color="blue">materially</font> impair our business</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our growth has come from <font color="blue">acquisition</font>s, and we may     make  more <font color="blue">acquisition</font>s in the future as part of our <font color="blue">continuing growth</font>     strategy</td>
    </tr>
    <tr>
      <td>This <font color="blue"><font color="blue">growth strategy</font> subjects us</font> to <font color="blue">numerous risks</font></td>
    </tr>
    <tr>
      <td>A very <font color="blue">important aspect</font> of our <font color="blue">growth strategy</font> has been and continues to be     pursuing strategic <font color="blue">acquisition</font>s of related businesses that we believe can     expand or <font color="blue">complement</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Since March </font>2000, we have <font color="blue">substantially</font>     grown our business through the <font color="blue">completion</font> of 11 <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>We did not     complete any <font color="blue">acquisition</font>s in 2005, but we are continuing to <font color="blue">explore future</font>     <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>require <font color="blue">significant</font> capital resources and divert     <font color="blue">management</font>’s attention from our existing business</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font><font color="blue">also entail</font>     an  inherent  risk that we <font color="blue">could become</font> subject to <font color="blue">contingent</font> or other     <font color="blue">liabilities</font>, including <font color="blue">liabilities</font> arising <font color="blue">from events</font> or conduct pre-dating     our <font color="blue">acquisition</font> of a business that were not known to us at the time of     <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>We  may also incur <font color="blue">significant</font>ly greater <font color="blue">expenditures</font> in     <font color="blue">integrating</font> an acquired business than we had anticipated at the time of its     purchase</td>
    </tr>
    <tr>
      <td>In  addition, <font color="blue">acquisition</font>s may create <font color="blue">unanticipated tax</font> and     <font color="blue">accounting</font> problems, including the <font color="blue">possibility</font> that we might be required to     write-off goodwill which we have paid for in <font color="blue"><font color="blue">connection</font> with</font> an <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>A key element of our <font color="blue">acquisition</font> strategy has been to retain <font color="blue">management</font> of     acquired businesses to operate the acquired business for us</td>
    </tr>
    <tr>
      <td>Many of these     <font color="blue">individuals</font>  maintain  important contacts with clients of the acquired     business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to retain these <font color="blue">individuals</font> could <font color="blue">materially</font> impair     the value of an acquired business</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">successfully</font> identify and     consummate future <font color="blue">acquisition</font>s or to manage and integrate the <font color="blue">acquisition</font>s     we make could have a material adverse effect on our business, financial     condition or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that:         •  we will identify suitable <font color="blue">acquisition</font> candidates;         •  we will receive the required <font color="blue">consent under</font> our outstanding credit     <font color="blue">facility</font>;         •  we can consummate <font color="blue">acquisition</font>s on acceptable terms;         •  we can <font color="blue">successfully</font> integrate any acquired business into our <font color="blue">operations</font>     or <font color="blue">successfully</font> manage the <font color="blue">operations</font> of any acquired business; or         •  we will be able to retain an acquired company’s <font color="blue">significant</font> client     relationships, goodwill and <font color="blue">key personnel</font> or otherwise realize the intended     benefits of any <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>Our credit <font color="blue">facility</font> contains certain restrictive covenants that, absent the     consent of the <font color="blue">administrative agent on behalf</font> of the <font color="blue">lenders under</font> the     credit <font color="blue">facility</font>, limit our ability to enter into <font color="blue">acquisition</font>s by setting     <font color="blue">limits on</font> the <font color="blue">maximum aggregate amount</font>s of cash we can pay in <font color="blue">acquisition</font>     <font color="blue">consideration</font> in any <font color="blue">fiscal year</font> and the <font color="blue">maximum aggregate amount</font> of all     <font color="blue">acquisition</font> <font color="blue">consideration</font> paid during the term of the credit <font color="blue">facility</font>, as     <font color="blue">well as restricting</font> the terms of equity <font color="blue">consideration</font> paid in <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________    [87]Table of <font color="blue">Contents       </font>We are subject to changes in <font color="blue">outsourcing trends</font> and <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>     <font color="blue">affecting</font>  the branded pharmaceutical, bio<font color="blue">technology</font>, <font color="blue">generic drug</font> and     medical  device  industries <font color="blue">which could</font> <font color="blue">adversely</font> affect our operating     results</td>
    </tr>
    <tr>
      <td>Economic factors and industry and <font color="blue">regulatory</font> trends that affect our primary     clients, branded pharmaceutical, bio<font color="blue">technology</font>, <font color="blue">generic drug</font> and medical     device  companies, also affect our business and operating results</td>
    </tr>
    <tr>
      <td>The     outsourcing of <font color="blue">drug <font color="blue">development</font></font> <font color="blue">activities</font> grew <font color="blue">substantially</font> during the     past decade and we <font color="blue">benefited from</font> this trend</td>
    </tr>
    <tr>
      <td>If these <font color="blue">industries reduce</font> the     outsourcing of their <font color="blue">clinical research</font> and other <font color="blue">drug <font color="blue">development</font></font> projects,     our <font color="blue">operations</font> will be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">continuing negative trend could</font>     have an <font color="blue">ongoing adverse</font> effect on our business, results of <font color="blue">operations</font> or     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Numerous <font color="blue">governments</font> have <font color="blue">undertaken efforts</font> to control     growing healthcare costs through legislation, regulation and voluntary     <font color="blue"><font color="blue">agreement</font>s</font>  with  <font color="blue">medical care providers</font> and <font color="blue">pharmaceutical companies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue">regulatory</font> changes under <font color="blue">consideration</font> include the <font color="blue">mandatory</font>     <font color="blue">substitution</font> of <font color="blue"><font color="blue">generic drug</font>s</font> for innovator drugs, relaxation in the scope     of <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> or the <font color="blue">introduction</font> of <font color="blue">simplified drug approval</font>     procedures</td>
    </tr>
    <tr>
      <td>If future <font color="blue">regulatory</font> cost containment efforts limit the profits     which can be <font color="blue">derived from new</font> and <font color="blue"><font color="blue">generic drug</font>s</font> or if <font color="blue">regulatory</font> approval     standards are relaxed, our <font color="blue">clients may reduce</font> the business they outsource to     us</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the likelihood of any of these events</td>
    </tr>
    <tr>
      <td>If branded pharmaceutical, bio<font color="blue">technology</font>, <font color="blue">generic drug</font> or medical device     <font color="blue">companies reduce</font> their <font color="blue">expenditures</font>, our <font color="blue">future revenue</font> and <font color="blue">profitability</font>     may be reduced</td>
    </tr>
    <tr>
      <td>Our business and <font color="blue">continued expansion depend on</font> the research and <font color="blue">development</font>     <font color="blue">expenditures</font>  of  our  clients  which  in  turn  is  <font color="blue">impacted by</font> their     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If these companies want to <font color="blue">reduce costs</font>, they may proceed     <font color="blue">with fewer <font color="blue">clinical trial</font>s</font> and other <font color="blue">drug <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>An <font color="blue">economic downturn</font>     or  other <font color="blue">factors may</font> cause our clients to decrease their research and     <font color="blue">development</font> <font color="blue">expenditures</font> which would <font color="blue">adversely</font> affect our <font color="blue">future revenue</font> and     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If we do not continue to generate a large number of <font color="blue">new client contracts</font>, or     if our <font color="blue">clients cancel</font> or <font color="blue">defer contracts</font>, our future <font color="blue">profitability</font> may be     <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">early stage contracts</font> are short term and our <font color="blue">late stage contracts</font>     <font color="blue"><font color="blue">generally</font> extend over</font> a period of one to two years, although some may be of     <font color="blue">longer duration</font></td>
    </tr>
    <tr>
      <td>However, all of our contracts are <font color="blue"><font color="blue">generally</font> cancelable by</font>     our <font color="blue">clients with</font> little or no notice</td>
    </tr>
    <tr>
      <td>A client may cancel or <font color="blue">delay existing</font>     <font color="blue">contracts with us at</font> its <font color="blue">discretion</font> and is likely to do so for a variety of     reasons, including:         •  <font color="blue">manufacturing problems</font> resulting in a shortage or <font color="blue">un<font color="blue">availability</font></font> of the     drug we are testing;         •  a <font color="blue">decision by</font> a client to de-emphasize or cancel the <font color="blue">development</font> of a     drug;         •  <font color="blue">unexpected <font color="blue">clinical trial</font></font> results;         •  <font color="blue">adverse participant reaction</font> to a drug;         •  an action by <font color="blue">regulatory</font> authorities (for example, in the United States,     the FDA, and in Canada, the TPD);         •  <font color="blue">continued publicity</font> relating to the Senate Finance Committee’s interest     in our Miami <font color="blue">facility</font>;         •  inadequate <font color="blue">participant enrollment</font>; and         •  any of the <font color="blue">factors discussed</font> in the other <font color="blue">risk factors</font> relating to     issues regarding our Miami <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>All of these factors are beyond our control and we must <font color="blue">continually</font> replace     our  existing contracts with new contracts to sustain our revenue</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">inability</font> to <font color="blue">generate new contracts on</font> a <font color="blue">timely basis would</font> have a material     adverse  effect  on  our business, <font color="blue">financial condition</font>, and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, since a large portion of our operating costs are     <font color="blue">relatively</font> fixed, <font color="blue">variations</font> in the timing and progress of contracts can     <font color="blue">materially</font>  affect our financial results</td>
    </tr>
    <tr>
      <td>The loss or delay of a large     project or contract or the loss or delay of <font color="blue">multiple smaller contracts could</font>     have a material adverse effect on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have experienced <font color="blue">termination</font>, <font color="blue">cancellation</font> and     delay of <font color="blue">contracts by clients from</font> time to                                         27       _________________________________________________________________    [88]Table of <font color="blue">Contents       </font>time in the past in the <font color="blue">ordinary course</font> of our business</td>
    </tr>
    <tr>
      <td>Moreover, our <font color="blue">Miami     </font><font color="blue">facility</font> has <font color="blue">recently lost</font> business and <font color="blue">clients as described</font> in Item 1     “<font color="blue">Issues Relating </font>to our Miami Facility” of this Report</td>
    </tr>
    <tr>
      <td>At any given time, one or a limited number of <font color="blue">clients may account</font> for a     large percentage of our revenue, which means that we could face a greater     risk of loss of revenue if we lose a <font color="blue">major client</font></td>
    </tr>
    <tr>
      <td>Historically, a small number of clients have generated a large percentage of     our net revenue in any <font color="blue">given period</font></td>
    </tr>
    <tr>
      <td>In each of 2005, 2004 and 2003, no     <font color="blue">client provided</font> more than 10prca of our <font color="blue">direct revenue</font>, but our 10 largest     <font color="blue">clients provided <font color="blue">approximately</font></font> 40prca, 31prca and 38prca, respectively, of our direct     revenue</td>
    </tr>
    <tr>
      <td><font color="blue">PharmaNet </font><font color="blue">also relies on</font> a limited number of <font color="blue">clients which generate</font>     a <font color="blue">significant</font> percentage of its <font color="blue">direct revenue</font></td>
    </tr>
    <tr>
      <td>During 2005, 2004 and 2003     <font color="blue">direct revenue</font> from four of PharmaNet’s clients, provided <font color="blue">approximately</font>     38dtta8prca,  41dtta4prca  and  34dtta7prca of PharmaNet’s <font color="blue">direct revenue</font>, respectively</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>that <font color="blue">constitute</font> our <font color="blue">largest clients vary from year</font> to year, and     our <font color="blue">direct revenue</font> from individual <font color="blue">clients fluctuates each year</font></td>
    </tr>
    <tr>
      <td>If we lose     one or more <font color="blue">major client</font>s in the future or if one or more <font color="blue">clients encounter</font>     financial <font color="blue"><font color="blue">difficult</font>ies</font>, our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may bear <font color="blue">financial risk</font></font> if we under-price our contracts or <font color="blue">overrun cost</font>     estimates</td>
    </tr>
    <tr>
      <td>We bear the <font color="blue">financial risk</font> if we initially under-price our contracts or     <font color="blue">otherwise overrun</font> our cost estimates</td>
    </tr>
    <tr>
      <td>Such under-pricing or <font color="blue">significant</font> cost     <font color="blue">overruns could</font> have a material adverse effect on our business, results of     <font color="blue">operations</font>, <font color="blue">financial condition</font> and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>If we are not able to remediate the material <font color="blue">weaknesses</font> relating to our     <font color="blue">internal controls</font> or if we <font color="blue">incur further instances</font> of <font color="blue">breakdowns</font> in our     <font color="blue">internal controls</font>, current and <font color="blue">potential <font color="blue">stockholders</font> could lose confidence</font>     in our financial reporting, <font color="blue">which would harm</font> our business and the price of     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In  <font color="blue">connection</font>  with  the  internal  control  audit for the year ended     <font color="blue">December </font>31,  2005,  our <font color="blue">management</font> assessed our <font color="blue">internal control over</font>     financial reporting and concluded that two material <font color="blue">weaknesses</font> existed</td>
    </tr>
    <tr>
      <td>We     have <font color="blue">taken two</font> steps to <font color="blue">remediate both</font> material <font color="blue">weaknesses</font>, which related to     too many <font color="blue">adjusting entries</font> and the failure to identity and <font color="blue">evaluate as well</font>     as disclose certain related party information to our Audit <font color="blue">Committee </font>and our     <font color="blue">independent</font>  registered public <font color="blue">accounting</font> firm</td>
    </tr>
    <tr>
      <td>In 2006, we have hired     <font color="blue">additional</font> <font color="blue">accounting</font> personnel to address the first material weakness</td>
    </tr>
    <tr>
      <td>In     late <font color="blue">December </font>2005, our <font color="blue">Board of Directors</font> adopted a resolution requiring     all related <font color="blue">party <font color="blue"><font color="blue">transaction</font>s</font></font> be <font color="blue">first approved by</font> our Audit <font color="blue">Committee </font>and     then by the full <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Recently </font>we amended our <font color="blue">Code of Ethics     </font>to require our human resources department to approve in writing the hiring     of all employees</td>
    </tr>
    <tr>
      <td>Human <font color="blue">resources will</font> make the <font color="blue">appropriate</font> related party     inquiries  and  forward  the information when <font color="blue">appropriate</font> to the Audit     Committee</td>
    </tr>
    <tr>
      <td>We believe these <font color="blue">remediation</font> efforts will enhance our ability to     identity and evaluate and disclose related <font color="blue">party <font color="blue"><font color="blue">transaction</font>s</font></font> to our Audit     <font color="blue">Committee </font>and our <font color="blue">independent</font> registered public <font color="blue">accounting</font> firm and thereby     remediate the second material weakness</td>
    </tr>
    <tr>
      <td>While <font color="blue">remediating</font> these material     <font color="blue">weaknesses</font>  is  a  very <font color="blue">high priority</font> for our <font color="blue">management</font> and our Audit     Committee, we <font color="blue">cannot assure</font> you that our <font color="blue">independent</font> registered public     <font color="blue">accounting</font> firm will agree with our <font color="blue">management</font>’s assessment that we have     remediated  them  or  that  we will not <font color="blue">encounter further instances</font> of     <font color="blue">breakdowns</font>  in  our  <font color="blue">internal control over</font> financial reporting</td>
    </tr>
    <tr>
      <td><font color="blue">Public     </font><font color="blue">disclosure</font> of these material <font color="blue">weaknesses</font> or a failure to promptly complete     our <font color="blue">remediation</font> effort could cause our <font color="blue">common stock</font> price to fall</td>
    </tr>
    <tr>
      <td>Moreover,     no matter how good a system of internal control is, it can be <font color="blue">circumvented</font>     by people who engage in improper action</td>
    </tr>
    <tr>
      <td>In such event, our results of     <font color="blue">operations</font> could be distorted</td>
    </tr>
    <tr>
      <td>If the improper activity is material, once     discovered and publicly disclosed, our <font color="blue">common stock</font> price could <font color="blue">materially</font>     decline</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">indebtedness</font>  may  impact  our <font color="blue">financial condition</font> and results of     <font color="blue">operations</font> and the terms of our outstanding <font color="blue">indebtedness</font> may limit our     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>31, 2005, we had <font color="blue">approximately</font> dlra168dtta2 million of <font color="blue">consolidated</font>     <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td><font color="blue">Subject  </font>to  applicable <font color="blue">restrictions</font> in our outstanding     <font color="blue">indebtedness</font>, we may incur <font color="blue">additional</font> <font color="blue">indebtedness</font> in the future</td>
    </tr>
    <tr>
      <td>28       _________________________________________________________________    [89]Table of <font color="blue">Contents       </font>Our level of <font color="blue">indebtedness</font> will have <font color="blue">several important effects on</font> our future     <font color="blue">operations</font>, including, <font color="blue">without limitation</font>:         •  we may be required to use a portion of our cash flow from <font color="blue">operations</font>     for the payment of principal and <font color="blue">interest due on</font> our outstanding     <font color="blue">indebtedness</font>;         •  our outstanding <font color="blue">indebtedness</font> and leverage <font color="blue">will increase</font> the impact of     negative changes in <font color="blue">general economic</font> and industry <font color="blue">conditions</font>, as well as     <font color="blue"><font color="blue">competitive</font> pressures</font>; and         •  the level of our outstanding <font color="blue">indebtedness</font> may affect our ability to     obtain <font color="blue">additional</font> financing for working capital, capital <font color="blue">expenditures</font> or     <font color="blue">general corporate purposes</font></td>
    </tr>
    <tr>
      <td>dlra17dtta0 million of our current outstanding <font color="blue">indebtedness</font> bears interest at a     floating  rate  tied  to  LIBOR and dlra143dtta75 million of our outstanding     <font color="blue">indebtedness</font> bears interest at a fixed rate of 2dtta25prca per year</td>
    </tr>
    <tr>
      <td>Accordingly,     if  interest rates increase, whether <font color="blue">generally</font> or as the result of our     lender’s requirement in <font color="blue"><font color="blue">connection</font> with</font> a proposed <font color="blue">amendment</font>, then the     amount of the <font color="blue">interest <font color="blue">payments on</font></font> our floating rate <font color="blue">indebtedness</font> will also     increase</td>
    </tr>
    <tr>
      <td>General <font color="blue">economic <font color="blue">conditions</font></font>, industry cycles and financial,     business and other factors <font color="blue">affecting</font> our <font color="blue">operations</font>, many of which are     beyond our control, may affect our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>As a result, these     and other <font color="blue">factors may</font> affect our ability to make principal and interest     <font color="blue">payments on</font> our <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>Our business might not continue to generate     cash  flow at or above <font color="blue">current levels</font></td>
    </tr>
    <tr>
      <td>Moreover, if we are required to     <font color="blue">repatriate foreign earnings</font> in order to pay our <font color="blue">debt service</font>, we may incur     <font color="blue">additional</font> income taxes</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot generate sufficient cash flow from</font>     <font color="blue">operations</font> in the future to service our <font color="blue">indebtedness</font>, we may, among other     things:         •  seek <font color="blue">additional</font> financing in the debt or <font color="blue">equity markets</font>;         •  seek to refinance or <font color="blue">restructure</font> all or a portion of our <font color="blue">indebtedness</font>;         •  <font color="blue">sell selected assets</font>; or         •  reduce or delay planned capital <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>These  measures  might  not  be sufficient to <font color="blue">enable us</font> to service our     <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>In addition, any financing, refinancing or sale of assets     might not be <font color="blue">available on economically</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>Furthermore, our credit <font color="blue">facility</font> contains certain restrictive covenants     <font color="blue">which will affect</font>, and in many respects <font color="blue">significant</font>ly limit or prohibit,     among other things, our ability to:         •  incur <font color="blue">indebtedness</font>;         •  create liens;         •  make <font color="blue">investment</font>s or loans;         •  engage in <font color="blue"><font color="blue"><font color="blue">transaction</font>s</font> with affiliates</font>;         •  <font color="blue">pay dividends</font> or make other <font color="blue">distributions on</font>, or redeem or repurchase,     <font color="blue">capital stock</font>;         •  issue <font color="blue">capital stock</font>;         •  make capital <font color="blue">expenditures</font>;         •  <font color="blue">sell assets</font>; and         •  <font color="blue">pursue mergers</font> or <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>As of the date of this Report, we <font color="blue">cannot borrow further on</font> the revolving     line of credit which is part of our credit <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We recently received a     waiver of <font color="blue">certain violations under</font> the credit <font color="blue">facility</font> as of <font color="blue">December </font>31,     2005</td>
    </tr>
    <tr>
      <td>We are seeking to amend the credit <font color="blue">facility</font> to <font color="blue">permit us</font> to re-borrow     under it, but <font color="blue">cannot assure</font> you we will be successful</td>
    </tr>
    <tr>
      <td>Additionally, we are     in violation of certain credit <font color="blue">facility</font> covenants at March 31, 2006 for the     reasons expressed under “Liquidity” in Item 7 of this Report</td>
    </tr>
    <tr>
      <td>29       _________________________________________________________________    [90]Table of <font color="blue">Contents       </font>We may not have <font color="blue">sufficient funds</font> to pay the <font color="blue">principal return upon <font color="blue">conversion</font></font>     or  to  repurchase  our  outstanding  convertible  senior  notes under     <font color="blue">circumstances</font> when we are required to do so</td>
    </tr>
    <tr>
      <td>We have outstanding dlra143dtta75 million in <font color="blue">aggregate <font color="blue">principal amount</font></font> of our     2dtta25prca convertible senior notes due 2024</td>
    </tr>
    <tr>
      <td>The notes are <font color="blue">convertible at</font> the     option of the <font color="blue">holders at</font> any time</td>
    </tr>
    <tr>
      <td>The <font color="blue">initial <font color="blue">conversion</font> rate</font> of the notes     is 24dtta3424 shares of <font color="blue">common stock</font> per dlra1cmam000 <font color="blue">principal amount</font> of the notes</td>
    </tr>
    <tr>
      <td>This  is  equivalent  to  an <font color="blue">initial <font color="blue">conversion</font> price</font> of <font color="blue">approximately</font>     dlra41dtta08 per share of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>However, the notes provide for what is     known  as “net share settlement” upon <font color="blue">conversion</font></td>
    </tr>
    <tr>
      <td>This means that upon     <font color="blue">conversion</font> of the notes, we will be required to pay up to dlra1cmam000 in cash,     per dlra1cmam000 <font color="blue">principal amount</font> of notes, and, if applicable, issue a number of     shares of our <font color="blue">common stock</font> <font color="blue">based upon</font> the <font color="blue">conversion</font> value in excess of the     <font color="blue">principal amount</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">conversion</font> value of the notes is <font color="blue">based on</font> the volume     weighted average price of our <font color="blue">common stock</font> for the <font color="blue">ten trading day period</font>     commencing the <font color="blue">second trading day</font> after we receive notice of <font color="blue">conversion</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">conversion</font> value must be <font color="blue">paid as soon as practicable</font> after it is determined</td>
    </tr>
    <tr>
      <td>In addition, holders of the notes may require us to purchase their notes for     cash on August 15, 2009, August 15, 2014 and August 15, 2019 and, under     certain <font color="blue">circumstances</font>, in the event of a “<font color="blue">fundamental</font> change”, as defined in     the <font color="blue">indenture under which</font> the notes were issued</td>
    </tr>
    <tr>
      <td>Further, if a <font color="blue">fundamental</font>     change  occurs  prior to August 15, 2009, we will be required to pay a     “make-whole  premium” in addition to the <font color="blue">repurchase price which may</font> be     <font color="blue">payable at</font> our election in cash or shares of our <font color="blue">common stock</font>, valued at 97prca     of the then current <font color="blue">market price</font>, or a <font color="blue">combination</font> of both</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient funds</font> at any such time to make the required     payment upon <font color="blue">conversion</font> or to purchase the notes and we may not be able to     raise <font color="blue">sufficient funds</font> to satisfy our <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>Furthermore, the terms of     our existing credit <font color="blue">facility</font> contains, and the terms of other <font color="blue">indebtedness</font>     that we may incur in the future may contain, financial covenants or other     provisions that could be <font color="blue">violated by payment</font> of the required <font color="blue">amounts upon</font>     <font color="blue">conversion</font> or the repurchase of the notes</td>
    </tr>
    <tr>
      <td>Our failure to pay the required     amounts on <font color="blue">conversion</font> of any of the notes when converted or to repurchase     any of the notes when we are required to do so would result in an event of     default  with  respect  to the notes, <font color="blue">which could</font> result in the entire     <font color="blue">outstanding principal balance</font> and <font color="blue">accrued but unpaid interest on</font> all of the     notes being <font color="blue">accelerated</font> and <font color="blue">could also</font> result in an event of <font color="blue">default under</font>     our other outstanding <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>Our operating results can be expected to <font color="blue">fluctuate from period</font> to period</td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations</font> are <font color="blue">usually due</font> to the level of new business awards in a     particular  period  and  the  timing  of  the <font color="blue">initiation</font>, progress, or     <font color="blue">cancellation</font> of <font color="blue">significant</font> projects</td>
    </tr>
    <tr>
      <td>Even a short <font color="blue">acceleration</font> or delay in     such  projects  could have a material effect on our results in a given     reporting period</td>
    </tr>
    <tr>
      <td>Varying periodic results could <font color="blue">adversely</font> affect the price     of our <font color="blue">common stock</font> if investors react to our reporting operating results     which are less favorable than in a <font color="blue">prior period</font> or than those anticipated by     investors or the <font color="blue">financial community <font color="blue">generally</font></font></td>
    </tr>
    <tr>
      <td>If we are required to <font color="blue">write off goodwill</font> or other <font color="blue">intangible assets</font>, our     <font color="blue">financial position</font> and results of <font color="blue">operations</font> would be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>For  the year ended <font color="blue">December </font>31, 2005, we incurred a non-cash goodwill     <font color="blue"><font color="blue">impairment</font> charge</font> of dlra20dtta3 million relating to our Miami <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>had a material adverse effect on our results of <font color="blue">operations</font> for the year</td>
    </tr>
    <tr>
      <td>We     had goodwill and other <font color="blue">intangible assets</font> of <font color="blue">approximately</font> dlra331dtta1 million and     dlra311dtta2 million (after deducting the <font color="blue"><font color="blue">impairment</font> charge</font>) as of <font color="blue">December </font>31,     2004 and <font color="blue">December </font>31, 2005, respectively, which <font color="blue">constitute</font>d <font color="blue">approximately</font>     59dtta3prca and 54dtta4prca, respectively, of our <font color="blue">total assets</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">periodically evaluate</font>     goodwill  and  other  intangible  assets  for  <font color="blue">impairment</font></td>
    </tr>
    <tr>
      <td>Any future     <font color="blue">de<font color="blue">termination</font></font>  requiring the write off of a <font color="blue">significant</font> portion of our     goodwill or other <font color="blue">intangible assets</font> could <font color="blue">adversely</font> affect our results of     <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>30       _________________________________________________________________    [91]Table of <font color="blue">Contents       </font>Our business is subject to international economic, political and other risks     that  could  <font color="blue">negatively</font>  affect our results of <font color="blue">operations</font> or financial     position</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our revenue is <font color="blue">derived from countries outside</font> the     United  States</td>
    </tr>
    <tr>
      <td>Further, we anticipate that <font color="blue">revenue from international</font>     <font color="blue">operations</font> may grow in the future</td>
    </tr>
    <tr>
      <td>Accordingly, our business is subject to     <font color="blue">risks <font color="blue">associated with</font></font> doing business <font color="blue">internationally</font>, including:         •  Less <font color="blue">stable political</font> and <font color="blue">economic environments</font> and changes in a     specific country’s or region’s political or <font color="blue">economic <font color="blue">conditions</font></font>;         •  <font color="blue">Potential </font><font color="blue">negative consequences from</font> changes in tax laws <font color="blue">affecting</font> our     ability to <font color="blue">repatriate profits</font>;         •  <font color="blue">Unfavorable </font>labor <font color="blue">regulations</font>;         •  Greater <font color="blue"><font color="blue">difficult</font>ies</font> in managing and staffing foreign <font color="blue">operations</font>;         •  Currency <font color="blue">fluctuations</font>;         •  Changes in trade policies, <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> and other barriers;         •  Civil unrest or other <font color="blue">catastrophic events</font>; and         •  Longer <font color="blue">payment cycles</font> of <font color="blue">foreign customers</font> and <font color="blue"><font color="blue">difficult</font>y collecting</font>     <font color="blue">receivables</font> in <font color="blue">foreign <font color="blue"><font color="blue">jurisdiction</font>s</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">realization</font> of any of these or     other <font color="blue">risks <font color="blue">associated with</font></font> operating in <font color="blue">foreign countries could</font> have a     material adverse effect on our business, results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>Our substantial non-United States <font color="blue">operations</font> expose us to <font color="blue">currency risks</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial statements</font> are <font color="blue">denominated</font> in US dollars, and <font color="blue">accordingly</font>,     changes in the <font color="blue">exchange rate between</font> the <font color="blue">Canadian </font>dollar, Euros or other     foreign  currencies  and  the  US dollar could <font color="blue">materially</font> affect the     <font color="blue">translation</font> of our <font color="blue">subsidiaries</font>’ financial results into US dollars for     purposes  of  reporting our <font color="blue">consolidated</font> financial results</td>
    </tr>
    <tr>
      <td>Due to the     <font color="blue">acquisition</font> of PharmaNet, which has <font color="blue">locations worldwide</font>, we are subject to     <font color="blue">exchange rate gains</font> and losses for <font color="blue">multiple currencies</font></td>
    </tr>
    <tr>
      <td>We also may be     subject to <font color="blue">foreign currency <font color="blue">transaction</font> risk</font> when our <font color="blue">service contracts</font> are     <font color="blue">denominated</font> in a currency other than the currency in which we <font color="blue">incur expenses</font>     or earn fees related to <font color="blue">such contracts</font></td>
    </tr>
    <tr>
      <td>For example, our <font color="blue">Canadian </font><font color="blue">operations</font>     often perform services for a fixed price <font color="blue">denominated</font> in US dollars or in     Euros while their payroll and other expenses are primarily <font color="blue">Canadian </font>dollar     expenses</td>
    </tr>
    <tr>
      <td>In 2005, we adopted a <font color="blue">formal foreign currency risk hedging policy</font>     to attempt to mitigate this risk in the future</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we     will  be successful in limiting <font color="blue">risks <font color="blue">associated with</font></font> foreign currency     <font color="blue"><font color="blue">transaction</font>s</font></td>
    </tr>
    <tr>
      <td>Although we initiated hedging <font color="blue"><font color="blue">transaction</font>s</font> in 2005 to seek to     mitigate our foreign <font color="blue">currency risks</font>, none of the individual <font color="blue"><font color="blue">transaction</font>s</font>     were material</td>
    </tr>
    <tr>
      <td>We incurred a pre-tax loss from foreign currency <font color="blue"><font color="blue">transaction</font>s</font>     relating  to  our  foreign  <font color="blue">operations</font>  for  the year of <font color="blue">approximately</font>     dlra0dtta7 million or dlra0dtta02 per diluted share after taxes</td>
    </tr>
    <tr>
      <td>We could be <font color="blue"><font color="blue">adversely</font> affected</font> by tax law changes in Canada or in other     <font color="blue"><font color="blue">jurisdiction</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> in Canada <font color="blue">currently benefit from</font> favorable <font color="blue">corporate tax</font>     <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>We receive substantial tax credits in Canada from both the     <font color="blue">Canadian </font>federal and Quebec <font color="blue">governments</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">Canadian </font><font color="blue">operations</font> employ a     large  number  of  research and <font color="blue">development</font> employees which results in     <font color="blue">significant</font> expenses related to these services</td>
    </tr>
    <tr>
      <td>Due to the nature of these     services, the <font color="blue">Canadian </font><font color="blue">government subsidizes</font> a portion of these expenses     <font color="blue">through tax</font> credits that result in a <font color="blue">reduced <font color="blue">effective</font> tax rate as well as</font> a     <font color="blue">significant</font> deferred tax asset on our <font color="blue">balance sheet</font></td>
    </tr>
    <tr>
      <td>Further, any reduction in     the  <font color="blue">availability</font> or amount of these tax credits could have a material     adverse effect on our profits and cash flow from our <font color="blue">Canadian </font><font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Additionally, a large part of our <font color="blue">net earnings</font> is generated outside of the     United States, where tax rates are <font color="blue"><font color="blue">generally</font> lower</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">applicable foreign</font>     tax rates, particularly in Canada and Switzerland, increase, it will reduce     our <font color="blue">consolidated</font> <font color="blue">net earnings</font></td>
    </tr>
    <tr>
      <td>31       _________________________________________________________________    [92]Table of <font color="blue">Contents       </font>Governmental <font color="blue">authorities may question</font> our inter-company transfer pricing     policies or change their laws in a manner that <font color="blue">could increase</font> our <font color="blue">effective</font>     tax or <font color="blue">otherwise harm</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">As a United States </font>company doing business in <font color="blue">international markets through</font>     <font color="blue">subsidiaries</font>, we are subject to <font color="blue">foreign tax</font> and inter-company pricing laws,     including those relating to the flow of <font color="blue">funds between</font> our company and our     <font color="blue">subsidiaries</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulators in the United States </font>and in <font color="blue">foreign markets closely</font>     monitor  our  <font color="blue">corporate structure</font> and how we effect inter-company fund     transfers</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">regulators</font> challenge</font> our <font color="blue">corporate structure</font>, transfer pricing     <font color="blue">mechanisms</font> or inter-company transfers, our <font color="blue">operations</font> may be <font color="blue">negatively</font>     impacted  and our <font color="blue">effective</font> tax rate may increase</td>
    </tr>
    <tr>
      <td>Tax <font color="blue">rates vary from</font>     country to country and if <font color="blue">regulators</font> determine that our profits in one     <font color="blue"><font color="blue">jurisdiction</font> may</font> need to be increased, we may not be able to <font color="blue">fully utilize</font>     all  foreign  tax credits that are generated, which would increase our     <font color="blue">effective</font> tax rate</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be in <font color="blue">compliance with</font>     all applicable customs, exchange control and <font color="blue">transfer pricing laws despite</font>     our efforts to be aware of and to <font color="blue">comply with</font> such laws</td>
    </tr>
    <tr>
      <td>Further, if these     laws change, we may need to adjust our operating procedure and our business     could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we  are <font color="blue">smaller than</font> our largest <font color="blue"><font color="blue">competitor</font>s</font>, we may lack the     resources needed to <font color="blue">compete <font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>There are a large number of <font color="blue">drug <font color="blue">development</font></font> services companies ranging in     size  from  one  person firms to full service, global <font color="blue">drug <font color="blue">development</font></font>     <font color="blue">corporations</font></td>
    </tr>
    <tr>
      <td>Intense <font color="blue">competition may lead</font> to <font color="blue">price pressure</font> or other     <font color="blue">conditions</font> that could <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue"><font color="blue">competitor</font>s</font>     are <font color="blue">substantially</font> larger than us and have greater financial, human and other     resources</td>
    </tr>
    <tr>
      <td>We may lack the operating and <font color="blue">financial resources</font> needed to     <font color="blue">compete <font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>If  we do not continue to develop <font color="blue">new <font color="blue">assay methods</font></font> for our analytical     <font color="blue">applications</font>, we may be unable to <font color="blue">compete with</font> other <font color="blue">entities offering</font>     <font color="blue">bioanalytical laboratory services</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">must continuously</font> develop <font color="blue">assay methods</font> to <font color="blue">test drug products</font> in order to     meet  the  needs  of  our clients and <font color="blue">attract new clients</font></td>
    </tr>
    <tr>
      <td>In order to     <font color="blue">substantially</font> increase the business of our bioanalytical laboratories, which     <font color="blue">provide services</font> for branded pharmaceutical, bio<font color="blue">technology</font> and <font color="blue">generic drug</font>     companies,  we must be able to <font color="blue">provide solutions</font> for our clients</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>requires <font color="blue">staying abreast</font> of current <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> and identifying     methods and <font color="blue">applications</font> that <font color="blue">will assist</font> our clients in obtaining approval     for their products</td>
    </tr>
    <tr>
      <td>If we are not successful in developing new methods and     <font color="blue">applications</font>, we may lose our clients</td>
    </tr>
    <tr>
      <td>We <font color="blue">risk potential <font color="blue">liability</font></font> when conducting <font color="blue">clinical trial</font>s, <font color="blue">which could</font>     cost us large amounts of money</td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">clinical trial</font>s involve administering drugs</font> to humans in order to     determine the effects of the drugs</td>
    </tr>
    <tr>
      <td>By doing so, we are subject to the     <font color="blue">general risks</font> of <font color="blue">liability</font> to these persons, which include those relating     to:         •  adverse side effects and reactions resulting from administering these     drugs to a <font color="blue">clinical trial</font> participant;         •  <font color="blue">unintended consequences</font> resulting from the procedures and/or changes in     <font color="blue">medical practice</font> to which a <font color="blue">study participant may</font> be subject as part of a     <font color="blue">clinical trial</font>;         •  <font color="blue">improper administration</font> of these drugs; or         •  <font color="blue">potential professional malpractice</font> of our employees or <font color="blue">contractor</font>s,     including physicians</td>
    </tr>
    <tr>
      <td>Our <font color="blue">contracts may</font> not have adequate <font color="blue">indemnification</font> <font color="blue"><font color="blue">agreement</font>s</font> requiring our     clients  to  indemnify  us in the event of <font color="blue">adverse consequences</font> to our     <font color="blue">participants</font> caused by their drugs or <font color="blue">participation</font> in their trials</td>
    </tr>
    <tr>
      <td>We also     carry <font color="blue">liability</font> insurance but there is <font color="blue">no certainty as</font> to the adequacy, or     the continued <font color="blue">availability</font> at rates acceptable to us, of such <font color="blue">liability</font>     insurance</td>
    </tr>
    <tr>
      <td>We <font color="blue">could also</font> be held liable for other errors or omissions in     <font color="blue"><font color="blue">connection</font> with</font> our services</td>
    </tr>
    <tr>
      <td>If we do not perform our services to     <font color="blue">contractual</font> or <font color="blue">regulatory</font> standards, the <font color="blue">clinical trial</font> process could be     <font color="blue">adversely</font>  affected</td>
    </tr>
    <tr>
      <td>Additionally, if <font color="blue">clinical trial</font> services such as     <font color="blue">laboratory analysis</font> do not conform to <font color="blue">contractual</font> or <font color="blue">regulatory</font> standards,     trial <font color="blue">participants</font> could be affected</td>
    </tr>
    <tr>
      <td>If there is a damage claim not covered     by insurance, the <font color="blue">indemnification</font>                                         32       _________________________________________________________________    [93]Table of <font color="blue">Contents       </font><font color="blue">agreement</font> is not enforceable or <font color="blue">broad enough</font>, or our client is insolvent,     any  resulting <font color="blue">award against us could</font> result in our experiencing large     losses</td>
    </tr>
    <tr>
      <td>We  face a risk of <font color="blue">liability</font> from our handling and disposal of medical     wastes,  which  could cause us to incur <font color="blue">significant</font> costs or otherwise     <font color="blue">adversely</font> <font color="blue">affect us</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">clinical trial</font> <font color="blue">activities</font> and <font color="blue">laboratory services involve</font> the controlled     disposal  of <font color="blue">medical waste</font>s, which are considered <font color="blue">hazardous materials</font></td>
    </tr>
    <tr>
      <td>Although we may use reputable <font color="blue">third parties</font> to dispose of <font color="blue">medical waste</font>, we     <font color="blue">cannot completely eliminate</font> the risk of <font color="blue">accidental contamination</font> or injury     from these materials</td>
    </tr>
    <tr>
      <td>If this occurs, we could be held liable for clean-up     costs, damages, face <font color="blue">significant</font> fines, and face the temporary or permanent     shutdown of our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> applicable <font color="blue">governmental</font> <font color="blue">regulations</font> <font color="blue">could harm</font> our     operating results and reputation</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">regulatory</font> action, which in some <font color="blue"><font color="blue">jurisdiction</font>s</font> includes     criminal  sanctions,  if  we  fail  to <font color="blue">comply with</font> applicable laws and     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Failure to comply can also result in the <font color="blue">termination</font> of ongoing     research and <font color="blue">disqualification</font> of <font color="blue">data collected during</font> the <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>This  <font color="blue">could harm</font> our reputation, our prospects for future work and our     operating results</td>
    </tr>
    <tr>
      <td>A <font color="blue">finding by</font> the FDA that we are not in <font color="blue">compliance with</font>     GLP  standards for our laboratories, current GMP standards, and/or GCP     standards for our clinical <font color="blue">facilities</font> could <font color="blue">materially</font> and <font color="blue">adversely</font> affect     us</td>
    </tr>
    <tr>
      <td>Similarly, a <font color="blue">finding by</font> the TPD that we are not in <font color="blue">compliance with</font>     <font color="blue">Canadian </font>Good Manufacturing Practices, or <font color="blue">Canadian </font>GMP, standards, and/or     <font color="blue">Canadian </font>Good Clinical Practices, or <font color="blue">Canadian </font>GCPs, and/or other <font color="blue">legislative</font>     <font color="blue">requirements</font> for <font color="blue">clinical trial</font>s in Canada, could <font color="blue">materially</font> and <font color="blue">adversely</font>     <font color="blue">affect us</font></td>
    </tr>
    <tr>
      <td>In addition to the above United States and <font color="blue">Canadian </font>laws and     <font color="blue">regulations</font>, we must <font color="blue">comply with</font> the laws of all countries where we do     business, including laws governing <font color="blue">clinical trial</font>s in the <font color="blue">jurisdiction</font> where     the trials are performed</td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> applicable <font color="blue">requirements</font>     could  subject  us  to  <font color="blue">regulatory</font> risk, <font color="blue">liability</font> and potential costs     <font color="blue">associated with</font> redoing the trials <font color="blue">which could</font> damage our reputation and     <font color="blue">adversely</font> affect our operating results</td>
    </tr>
    <tr>
      <td>If  we lose the services of our <font color="blue">key personnel</font> or are unable to attract     <font color="blue">qualified staff</font>, our business could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">substantially</font> dependent upon the performance, contributions     and expertise of our senior <font color="blue">management</font> team, including, <font color="blue">among others</font>, Mr</td>
    </tr>
    <tr>
      <td>Jeffrey P McMullen, SFBC’s <font color="blue">chief executive officer</font>, the <font color="blue">executive committee</font>     comprised  of  20  members, and our <font color="blue">divisional presidents</font> and key vice     <font color="blue">presidents companywide</font></td>
    </tr>
    <tr>
      <td>In addition, some members of our senior <font color="blue">management</font>     team play a very <font color="blue">significant</font> role in the <font color="blue">generation</font> of new business and     retention of <font color="blue">existing clients</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also depend on</font> our ability to attract and     retain qualified <font color="blue">management</font>, professional and operating staff</td>
    </tr>
    <tr>
      <td>Our loss of     the services of any of the members of senior <font color="blue">management</font>, or any other key     executive, or our <font color="blue">inability</font> to continue to attract and retain qualified     personnel, could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends on</font> the continued <font color="blue">effective</font>ness and <font color="blue">availability</font> of our     information <font color="blue"><font color="blue">technology</font> <font color="blue">infrastructure</font></font>, and failures of this <font color="blue">infrastructure</font>     <font color="blue">could harm</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>To  remain  <font color="blue">competitive</font>  in  our  industry, we <font color="blue">must employ</font> information     <font color="blue">technologies</font> that capture, manage, and analyze the large streams of data     generated  during  our  clinical  trials in <font color="blue">compliance with</font> applicable     <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>In addition, because we <font color="blue">provide services</font> on a     <font color="blue">global basis</font>, we <font color="blue">rely extensively on</font> our <font color="blue">technology</font> to allow the <font color="blue">concurrent</font>     conduct  of  studies  and  work  <font color="blue">sharing around</font> the world</td>
    </tr>
    <tr>
      <td>As with all     information <font color="blue">technology</font>, our system is vulnerable to <font color="blue">potential damage</font> or     interruptions from fires, blackouts, telecommunications failures, and other     unexpected events, as well as to break-ins, sabotage, or <font color="blue">intentional</font> acts of     vandalism</td>
    </tr>
    <tr>
      <td>Given the extensive reliance of our business on this <font color="blue">technology</font>,     any substantial <font color="blue">disruption</font> or resulting loss of data that is not avoided or     corrected by our backup measures <font color="blue">could harm</font> our business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>33       _________________________________________________________________    [94]Table of <font color="blue">Contents       </font>Risks Related to Our Common <font color="blue">Stock     </font>  We may issue a substantial amount of our <font color="blue">common stock</font> in the <font color="blue">future which</font>     could cause dilution to <font color="blue">new investors</font> and otherwise <font color="blue">adversely</font> affect our     stock price</td>
    </tr>
    <tr>
      <td>An element of our <font color="blue">growth strategy</font> is to make <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>As part of our     <font color="blue">acquisition</font> strategy, we may issue <font color="blue">additional</font> shares of <font color="blue">common stock</font> as     <font color="blue">consideration</font> for such <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>These <font color="blue">issuances could</font> be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>To the extent that we make <font color="blue">acquisition</font>s and issue our shares of <font color="blue">common stock</font>     as <font color="blue">consideration</font>, your equity interest in us will be diluted</td>
    </tr>
    <tr>
      <td>Any such     <font color="blue">issuance will also increase</font> the number of <font color="blue">outstanding shares</font> of <font color="blue">common stock</font>     that will be eligible for sale in the future</td>
    </tr>
    <tr>
      <td>Persons receiving shares of     our <font color="blue">common stock</font> in <font color="blue"><font color="blue">connection</font> with</font> these <font color="blue">acquisition</font>s may be likely to sell     off their <font color="blue">common stock</font> rather than hold their shares for <font color="blue">investment</font>, which     may  impact  the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, the potential     issuance of <font color="blue">additional</font> shares in <font color="blue"><font color="blue">connection</font> with</font> anticipated <font color="blue">acquisition</font>s     <font color="blue">could lessen demand</font> for our <font color="blue">common stock</font> and result in a <font color="blue">lower price than</font>     <font color="blue">might otherwise</font> be obtained</td>
    </tr>
    <tr>
      <td>We plan to issue <font color="blue">common stock</font>, for <font color="blue">compensation</font>     purposes  and  in  <font color="blue"><font color="blue">connection</font> with</font> strategic <font color="blue"><font color="blue">transaction</font>s</font> or for other     purposes</td>
    </tr>
    <tr>
      <td>Recent changes in <font color="blue">accounting</font> standards could limit the <font color="blue">desirability</font> of     <font color="blue">granting stock options</font>, <font color="blue">which could</font> harm our ability to attract and retain     employees, and <font color="blue">could also</font> <font color="blue">negatively</font> impact our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Financial Accounting Standards Board </font>is requiring all companies to treat     the <font color="blue">fair value</font> of <font color="blue">stock options granted</font> to <font color="blue">employees as</font> an expense <font color="blue">effective</font>     for the <font color="blue">first interim</font> reporting period that begins after June 15, 2005</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>change became <font color="blue">effective</font> for us on January 1, 2006</td>
    </tr>
    <tr>
      <td>We and other companies     are required to record a <font color="blue">compensation</font> expense equal to the <font color="blue">fair value</font> of     <font color="blue">each stock option granted over</font> its <font color="blue">vesting period</font></td>
    </tr>
    <tr>
      <td>Previously, we were     <font color="blue">generally</font> not required to record <font color="blue">compensation</font> expense in <font color="blue"><font color="blue">connection</font> with</font>     employee  stock  option  grants</td>
    </tr>
    <tr>
      <td>We believe this change may reduce the     <font color="blue">attractiveness</font> of <font color="blue">granting stock options</font> because of the <font color="blue">additional</font> expense     <font color="blue">associated with</font> these grants, which would <font color="blue">negatively</font> impact our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>For example, had we been required to <font color="blue">expense stock option grants</font>     by applying the <font color="blue">measurement provisions</font> of <font color="blue">Statement </font>123(R), our <font color="blue">recorded net</font>     earnings for the years ended <font color="blue">December </font>31, 2004 and 2005 of <font color="blue">approximately</font>     dlra19dtta7 million and dlra4dtta8 million, respectively, would have <font color="blue">been reduced</font> to     <font color="blue">approximately</font> dlra15dtta7 million and a loss of dlra3dtta1 million, respectively</td>
    </tr>
    <tr>
      <td><font color="blue">Stock     </font>options are an <font color="blue">important employee recruitment</font> and retention tool, and we may     not be able to attract and retain <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">Statement </font>123(R)     did  not  apply  to <font color="blue">vested options as</font> of <font color="blue">December </font>31, 2005, in 2005 we     <font color="blue">accelerated</font>  the  vesting  of 462cmam059 out-of-the-money options held by     <font color="blue">PharmaNet </font><font color="blue">executives</font> and issued 263cmam544 vested options to 119 employees,     none of whom are <font color="blue">executive officers</font> and <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Beginning </font>in 2006, we     plan to eliminate or reduce issuance of stock options and issue lesser     amounts of restricted stock or restricted stock units which involve less     dilution, but <font color="blue">generally</font> result in income taxation to employees who receive     grants, unless delivery is deferred into the future</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of whether     we issue options or restricted stock, our future results of <font color="blue">operations</font> will     be <font color="blue">negatively</font> impacted</td>
    </tr>
    <tr>
      <td>Our stock price can be <font color="blue">extremely volatile</font>, and your <font color="blue">investment</font> could suffer     a decline in value</td>
    </tr>
    <tr>
      <td>The  trading  price of our <font color="blue">common stock</font> has been, and is likely to be,     volatile and could be subject to wide <font color="blue">fluctuations</font> in price in response to     <font color="blue">various factors</font>, many of which are beyond our control, including:         •  actual or anticipated <font color="blue">variations</font> in quarterly operating results,     including changes in our <font color="blue">guidance as</font> to <font color="blue">forecasted earnings</font>;         •  changes in financial estimates by securities analysts;         •  <font color="blue">media articles such as</font> the Bloomberg Reports;         •  <font color="blue">adverse events</font> arising in <font color="blue"><font color="blue">connection</font> with</font> our Miami <font color="blue">facility</font> including     events related to the property;         •  loss of a <font color="blue">major client</font> or contract;         •  <font color="blue">new service offerings introduced</font> or announced by our <font color="blue"><font color="blue">competitor</font>s</font>;                                         34       _________________________________________________________________    [95]Table of <font color="blue">Contents       </font>    •  changes in <font color="blue">market valuations</font> of other similar companies;         •  our <font color="blue">announcement</font> of <font color="blue">significant</font> <font color="blue">acquisition</font>s, strategic partnerships,     <font color="blue">joint ventures</font> or <font color="blue">capital commitments</font>;         •  <font color="blue">additions</font> or <font color="blue">departures</font> of <font color="blue">key personnel</font>; and         •  sales of our <font color="blue">common stock</font>, including short sales</td>
    </tr>
    <tr>
      <td>As  a result, investors could lose all or part of their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>In     addition, the <font color="blue">stock market</font> in general experiences <font color="blue">extreme price</font> and volume     <font color="blue">fluctuations</font> that are often unrelated and <font color="blue">disproportionate</font> to the operating     performance of companies</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our charter <font color="blue">documents</font> and under <font color="blue">Delaware </font>law may     make an <font color="blue">acquisition</font> of us, which may be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font>, more     <font color="blue">difficult</font>, <font color="blue">which could</font> depress our stock price</td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">incorporated</font> in Delaware</td>
    </tr>
    <tr>
      <td>Certain anti-takeover provisions of     <font color="blue">Delaware </font>law and our charter <font color="blue">documents</font> as currently in effect may make a     change in control of our company more <font color="blue">difficult</font>, even if a change in control     would be <font color="blue">beneficial</font> to the <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our charter <font color="blue">documents</font> provide that     our board of <font color="blue">directors</font> may issue, without a vote of our <font color="blue">stockholders</font>, one or     more series of <font color="blue">preferred stock</font> that has more <font color="blue">than one vote per</font> share</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">could permit</font> our board of <font color="blue">directors</font> to issue <font color="blue">preferred stock</font> to investors     who support our <font color="blue">management</font> and give <font color="blue">effective</font> control of our business to our     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Additionally,  issuance of <font color="blue">preferred stock</font> could block an     <font color="blue">acquisition</font> resulting in both a drop in the price of our <font color="blue">common stock</font> and a     decline in interest in the stock, <font color="blue">which could</font> make it more <font color="blue">difficult</font> for     <font color="blue">stockholders</font> to sell their shares</td>
    </tr>
    <tr>
      <td>This could cause the <font color="blue">market price</font> of our     <font color="blue">common stock</font> to drop <font color="blue">significant</font>ly, even if our business is performing well</td>
    </tr>
    <tr>
      <td>Our <font color="blue">bylaws also limit</font> who may call a <font color="blue">special meeting</font> of <font color="blue">stockholders</font> and     <font color="blue">establish advance</font> notice <font color="blue">requirements</font> for nomination for election to the     board  of <font color="blue">directors</font> or for <font color="blue">proposing matters</font> that can be acted upon at     <font color="blue">stockholder meetings</font></td>
    </tr>
    <tr>
      <td><font color="blue">Delaware </font>law also prohibits <font color="blue">corporations</font> from engaging     in a business <font color="blue">combination</font> with any holders of 15prca or more of their capital     stock until the holder has held the stock for three years unless, among     other <font color="blue">possibilities</font>, the board of <font color="blue">directors</font> approves the <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>Our     board  of <font color="blue">directors</font> may use these provisions to prevent changes in the     <font color="blue">management</font> and control of our company</td>
    </tr>
    <tr>
      <td>Also, <font color="blue">under applicable</font> <font color="blue">Delaware </font>law,     our board of <font color="blue">directors</font> may adopt <font color="blue">additional</font> anti-takeover measures in the     future</td>
    </tr>
    <tr>
      <td>In addition, provisions of certain contracts, such as employment     <font color="blue"><font color="blue">agreement</font>s</font> with our <font color="blue">executive officers</font>, may have an anti-takeover effect</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2005, our board of <font color="blue">directors</font> adopted a Shareholder Rights Plan,     which  has the effect of <font color="blue">deterring hostile takeovers</font></td>
    </tr>
    <tr>
      <td>Additionally, we     adopted an <font color="blue">amendment</font> to our Bylaws, <font color="blue">which temporarily</font> requires holders who     own  20prca  or  more  of  our  <font color="blue">common stock</font> to call a <font color="blue">special meeting</font> of     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">On January </font>1, 2007, the required <font color="blue">percentage drops back</font> to 10prca</td>
    </tr>
  </tbody>
</table>